{
  "id": 732888,
  "title": "Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock",
  "url": "https://urgent.news/2026/08/13/vera-therapeutics-president-and-ceo-marshall-fordyce-sells-1-96m-in",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-13T04:46:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/vera-therapeutics-president-and-ceo-marshall-fordyce-sells-196m-in-stock-93CH-4856595"
  },
  "original_language": "en",
  "account": "Marshall Fordyce, President and CEO of Vera Therapeutics, sold a significant amount of the company's Class A Common Stock on July 7, 2026. He traded 46,250 shares - roughly $1.96 million - at prices between $40.39 and $43.97 per share. Simultaneously, Fordyce purchased 46,250 shares through the exercise of stock options, paying $2.8968 per share, which totaled $133,977. Following these transactions, Fordyce holds 235,244 shares of Vera Therapeutics directly, along with 525,801 derivative securities in the form of stock options.\n\nVera Therapeutics has recently reported a loss per share of $1.52 in its second-quarter 2026 results, which was better than Goldman Sachs' estimate of $1.73. The company also received accelerated FDA approval for its drug Trutakna, aimed at treating IgA nephropathy. This development has led to increased interest from investors, with Guggenheim raising its price target for the company from $56 to $76, and Cantor Fitzgerald maintaining an Overweight rating with a $100 price target. However, H.C. Wainwright adjusted its price target for Vera Therapeutics from $125 to $90, taking into account competitive factors affecting drug market penetration. The company has also appointed Nancy Boman as chief regulatory officer, replacing William Turner, who is now a strategic advisor. These changes demonstrate Vera Therapeutics' ongoing strategic adjustments and regulatory milestones.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}